These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28732153)

  • 1. Hepatitis B and C Viruses and Biologics.
    Grewal P; Sanghera R
    Skin Therapy Lett; 2017 Jul; 22(4):7-9. PubMed ID: 28732153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.
    Degasperi E; Caprioli F; El Sherif O; Back D; Colombo M; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2016 Dec; 10(12):1373-1383. PubMed ID: 27718758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferon].
    Tamori A; Kawada N
    Nihon Rinsho; 2012 Apr; 70(4):620-4. PubMed ID: 22568143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral Research--16th International Congress: HBV and HCV. 27 April-1 May 2003, Savannah, GA, USA.
    Smee D
    IDrugs; 2003 Jun; 6(6):518-21. PubMed ID: 12861975
    [No Abstract]   [Full Text] [Related]  

  • 5. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.
    Potthoff A; Berg T; Wedemeyer H;
    Scand J Gastroenterol; 2009; 44(12):1487-90. PubMed ID: 19900055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-resistant viral hepatitis.
    Wright M; Main J; Thomas HC
    J Infect; 2000 Jul; 41(1):1-4. PubMed ID: 10942634
    [No Abstract]   [Full Text] [Related]  

  • 7. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.
    Meuleman P; Leroux-Roels G
    Antiviral Res; 2008 Dec; 80(3):231-8. PubMed ID: 18706933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
    Shakya N; Vedi S; Liang C; Agrawal B; Tyrrell DL; Kumar R
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6475-80. PubMed ID: 22985854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
    Renou C; Cadranel JF; Pariente A; Pénaranda G; Bourlière M; Halfon P; Igual JP; Harafa A; Muller P; Bertrand JJ; Laugier R
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1235-7. PubMed ID: 18989147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 11. Virology of hepatitis B and C viruses and antiviral targets.
    Pawlotsky JM
    J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment predictors of a sustained virologic response in hepatitis B and C.
    Kau A; Vermehren J; Sarrazin C
    J Hepatol; 2008 Oct; 49(4):634-51. PubMed ID: 18715665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection.
    Rautou PE; Asselah T; Saadoun D; Martinot M; Valla D; Marcellin P
    Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):1019-22. PubMed ID: 16894318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.
    Yotsuyanagi H; Koike K
    J Gastroenterol; 2007 May; 42(5):329-35. PubMed ID: 17530355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of HBV/HCV coinfection.
    Potthoff A; Manns MP; Wedemeyer H
    Expert Opin Pharmacother; 2010 Apr; 11(6):919-28. PubMed ID: 20166841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in antiviral agents: antiviral drug discovery for hepatitis viruses.
    Tanikawa K
    Curr Pharm Des; 2006; 12(11):1371-7. PubMed ID: 16611121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-based and animal models for hepatitis B and C viruses.
    Schinazi RF; Ilan E; Black PL; Yao X; Dagan S
    Antivir Chem Chemother; 1999 May; 10(3):99-114. PubMed ID: 10431609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B and C viruses: molecular identification and targeted antiviral therapies.
    Berenguer M; Wright TL
    Proc Assoc Am Physicians; 1998; 110(2):98-112. PubMed ID: 9542765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing a low-cost drug resistance database for viral hepatitis.
    Kuiken C
    Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.